2Swain SM,Whaley FS,Ewer MS.Congestive heart failure in patients treated with doxorubicin:a retrospective analysis of three trials[J].Cancer,2003,97(11):2869-2879. 被引量：1
3Yeh ET,Tong AT,Lenihan DJ,et al.Cardiovascular complications of cancer therapy:diagnosis,pathogenesis,and management[J].Circulation,2004,109(25):3122-3131. 被引量：1
4Nichols C,Roth B,Williams S,et al.No evidence of acute cardiovascular complications of chemotherapy for testicular cancer:An analysis of the testicular cancer intergroup study[J].J Clin Oncol,1992,10:760-765. 被引量：1
5Cianci G,Morelli MF,Cannita K,et al.Prophylactic options in patients with 5-fluorouracil associated cardiotoxicity[J].Br J Cancer,2003,88(10):1507-1509. 被引量：1
6Floyd JD,Nguyen DT,Lobins RL,et al.Cardiotoxicity of cancer therapy[J].J Clin Oncol,2005,23(30):7685-7696. 被引量：1
8Cersosimo RJ.Monoclonal antibodies in the treatment of cancer,Part 1[J].Am J Health Syst Pharm,2003,60(15):1531-1548. 被引量：1
9Burris H 3rd,Yardley D,Jones S,et al.Phase Ⅱ trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer[J].J Clin Oncol,2004,22(9):1621-1629. 被引量：1
10Olsen E,Duvic M,Frankel A,et al.Pivotal phase Ⅲ trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma[J].J Clin Oncol,2001,19(2):376-388. 被引量：1
